Vittal Vasista Regenxbio Inc. (RGNX) insider trading activity

Vittal Vasista is Chief Financial Officer of REGENXBIO Inc.. Currently has a direct ownership of 246,534 shares of RGNX, which is worth approximately $2.69 Million. The most recent transaction as insider was on Mar 19, 2024, when has been sold 20,041 shares (Common Stock) at a price of $3.76 per share, resulting in proceeds of $75,354. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 247K

0% 3M change

14.67% 12M change

Total Value Held $2.69 Million

Vittal Vasista Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 19 2024	BUY Exercise of conversion of derivative security	$75,354 $3.76 p/Share	20,041 Added 7.52%	246,534 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$81,385 $17.95 p/Share	4,534 Reduced 2.11%	210,467 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	16,026 Added 6.61%	226,493 Common Stock
May 31 2023	BUY Exercise of conversion of derivative security	$29,750 $0.85 p/Share	35,000 Added 14.0%	215,001 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$30,232 $22.68 p/Share	1,333 Reduced 0.99%	133,827 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	46,174 Added 20.42%	180,001 Common Stock
Aug 30 2022	SELL Open market or private sale	$72,576 $30.24 p/Share	2,400 Reduced 1.74%	135,160 Common Stock

Aug 05 2022	SELL Open market or private sale	$608,083 $35.19 p/Share	17,280 Reduced 11.16%	137,560 Common Stock
Aug 04 2022	SELL Open market or private sale	$14,000 $35.0 p/Share	400 Reduced 0.26%	154,840 Common Stock
Aug 01 2022	SELL Open market or private sale	$75,000 $31.25 p/Share	2,400 Reduced 1.52%	155,240 Common Stock
Jul 14 2022	SELL Open market or private sale	$14,040 $30.0 p/Share	468 Reduced 0.3%	157,640 Common Stock
Jul 13 2022	SELL Open market or private sale	$130,003 $30.01 p/Share	4,332 Reduced 2.67%	158,108 Common Stock
Jan 20 2022	BUY Exercise of conversion of derivative security	$25,415 $0.85 p/Share	29,900 Added 15.55%	162,440 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	8,900 Added 6.29%	132,540 Common Stock
Jul 27 2021	BUY Exercise of conversion of derivative security	$8,500 $0.85 p/Share	10,000 Added 7.48%	123,640 Common Stock
Jan 15 2021	SELL Open market or private sale	$12,610 $50.04 p/Share	252 Reduced 0.22%	113,640 Common Stock
Jan 14 2021	SELL Open market or private sale	$554,983 $50.03 p/Share	11,093 Reduced 8.88%	113,892 Common Stock
Jan 12 2021	SELL Open market or private sale	$210,042 $50.01 p/Share	4,200 Reduced 3.25%	124,985 Common Stock
Jan 08 2021	SELL Open market or private sale	$248,214 $47.36 p/Share	5,241 Reduced 3.9%	129,185 Common Stock
Jan 07 2021	SELL Open market or private sale	$549,900 $50.0 p/Share	10,998 Reduced 7.56%	134,426 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	12,400 Added 7.86%	145,424 Common Stock
Dec 24 2020	SELL Open market or private sale	$168,800 $50.0 p/Share	3,376 Reduced 2.48%	133,024 Common Stock
Dec 23 2020	SELL Open market or private sale	$1,056,411 $50.01 p/Share	21,124 Reduced 13.41%	136,400 Common Stock
Dec 11 2020	SELL Open market or private sale	$599,176 $40.17 p/Share	14,916 Reduced 8.65%	157,524 Common Stock
Dec 10 2020	SELL Open market or private sale	$904,715 $40.06 p/Share	22,584 Reduced 11.58%	172,440 Common Stock

Vittal Vasista

Chief Financial Officer

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGNX shares.

Notify only if

Value

Insider Trading

Get notified when an Regenxbio Inc. insider buys or sells RGNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENXBIO Inc.

Track Activities on RGNX

Account